BMS

CheckMate 7FL

NCT04109066

A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Status:

Recruiting

26459-200.png

III

Phase

Line of Therapy.png

Neoadjuvant

Line of Therapy

Disease Stage.png

Early Cancer

Disease Stage

Target.png

Biomarker(s)

ER+, HER2-

Investigational

Product

Nivolumab

Treatment Arms

o Nivolumab combined with neoadjuvant CT and adjuvant ET

o Placebo combined with neoadjuvant CT and adjuvant ET